Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL
Liu M, Robinson P, Yau C, Wallace A, Chien A, Stringer-Reasor E, Nanda R, Yee D, Albain K, Boughey J, Han H, Elias A, Kalinsky K, Clark A, Kemmer K, Isaacs C, Lang J, Lu J, Sanft T, DeMichele A, Hylton N, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, van't Veer L, Haugen P, Wilson A, Singhrao R, Asare S, Sanil A, Berry D, Esserman L. Abstract P3-09-02: Evaluation of a novel agent plus standard neoadjuvant therapy in early stage, high-risk HER2 negative breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2020, 80: p3-09-02-p3-09-02. DOI: 10.1158/1538-7445.sabcs19-p3-09-02.Peer-Reviewed Original ResearchPathological complete responseHER2 negative breast cancerI-SPY 2 TRIALWeeks of paclitaxelNegative breast cancerNeoadjuvant therapyBreast cancerHR-/HER2High-risk stage II/III breast cancerImmune-related adverse eventsPathologic complete response rateRandomized phase 2 trialStage II/III breast cancerHormone-receptorI-SPYEvaluate novel agentsGrade 3 colitisGrade 3 pneumonitisGrade 3 transaminitisPhase 2 trialPhase 3 trialBayesian predictive probability of successNeoadjuvant trialsWeekly paclitaxelComplete responseAbstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer
Onishi N, Li W, Newitt D, Harnish R, Gibbs J, Jones E, Nguyen A, Wilmes L, Joe B, Campbell M, Basu A, van’t Veer L, DiMichele A, Yee D, Berry D, Albain K, Boughey J, Chien A, Clark A, Edmiston K, Elias A, Ellis E, Euhus D, Han H, Isaacs C, Khan Q, Lang J, Lu J, Meisel J, Mitri Z, Nanda R, Northfelt D, Sanft T, Stringer-Reasor E, Viscusi R, Wallace A, Yung R, Melisko M, Perlmutter J, Rugo H, Schwab R, Symmans W, Asare S, Yau J, Yau C, Esserman L, Hylton N. Abstract PD9-05: Lack of background parenchymal enhancement suppression in breast MRI during neoadjuvant chemotherapy may be associated with inferior treatment response in hormone receptor positive breast cancer. Cancer Research 2020, 80: pd9-05-pd9-05. DOI: 10.1158/1538-7445.sabcs19-pd9-05.Peer-Reviewed Original ResearchPathological complete responseBackground parenchymal enhancementInferior treatment responseHormone receptor-positive breast cancerPathologic complete response rateReceptor-positive breast cancerPositive breast cancerTreatment responseHR cohortBreast cancerBreast MRINeoadjuvant chemotherapyNon-pCRDegree of BPEI-SPY 2 TRIALQuantitative background parenchymal enhancementStage II/III breast cancerContralateral breast parenchymaPost-NAC MRIHormone receptor statusHR+ breast cancerEffects of chemotherapyEnhanced suppressionStatistically significant associationHR+ cancers